Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.

Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris-Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS.

Cancer Immunol Res. 2019 Dec;7(12):2036-2051. doi: 10.1158/2326-6066.CIR-19-0152. Epub 2019 Sep 17.

PMID:
31530560
2.

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.

Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, García-Macías MDC, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E.

Oncotarget. 2017 Jun 27;8(26):43592. doi: 10.18632/oncotarget.18610. No abstract available.

3.

Trabectedin as a chemotherapy option for patients with BRCA deficiency.

Monk BJ, Lorusso D, Italiano A, Kaye SB, Aracil M, Tanović A, D'Incalci M.

Cancer Treat Rev. 2016 Nov;50:175-182. doi: 10.1016/j.ctrv.2016.09.009. Epub 2016 Sep 15. Review.

PMID:
27710871
4.

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.

Ordóñez JL, Amaral AT, Carcaboso AM, Herrero-Martín D, del Carmen García-Macías M, Sevillano V, Alonso D, Pascual-Pasto G, San-Segundo L, Vila-Ubach M, Rodrigues T, Fraile S, Teodosio C, Mayo-Iscar A, Aracil M, Galmarini CM, Tirado OM, Mora J, de Álava E.

Oncotarget. 2015 Aug 7;6(22):18875-90. doi: 10.18632/oncotarget.4303. Erratum in: Oncotarget. 2017 Jun 27;8(26):43592.

5.

Marine compounds inhibit growth of multiple myeloma in vitro and in vivo.

Steiner N, Ribatti D, Willenbacher W, Jöhrer K, Kern J, Marinaccio C, Aracil M, García-Fernández LF, Gastl G, Untergasser G, Gunsilius E.

Oncotarget. 2015 Apr 10;6(10):8200-9.

6.

Association between coenzyme Q10 and glucose transporter (GLUT1) deficiency.

Yubero D, O'Callaghan M, Montero R, Ormazabal A, Armstrong J, Espinos C, Rodríguez MA, Jou C, Castejon E, Aracil MA, Cascajo MV, Gavilan A, Briones P, Jimenez-Mallebrera C, Pineda M, Navas P, Artuch R.

BMC Pediatr. 2014 Nov 8;14:284. doi: 10.1186/s12887-014-0284-5.

7.

Paneth cells are also target of the ribotoxic lectin nigrin b.

Jiménez P, Gayoso MJ, Garrosa M, Córdoba-Díaz D, Cabrero P, Tejero J, Aracil M, Girbés T.

Histol Histopathol. 2014 Aug;29(8):1057-63. doi: 10.14670/HH-29.1057. Epub 2014 Feb 24.

PMID:
24563426
8.

Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.

Monk BJ, Kaye SB, Poveda A, Herzog TJ, Aracil M, Nieto A, Badri N, Parekh TV, Tanović A, Galmarini CM.

Gynecol Oncol. 2014 Jan;132(1):176-80. doi: 10.1016/j.ygyno.2013.10.032. Epub 2013 Nov 5.

PMID:
24211400
9.

Retraction: PM02734 (elisidepsin) induces caspase-independent cell death associated with features of autophagy, inhibition of the Akt/mTOR signaling pathway, and activation of death-associated protein kinase.

Ling YH, Aracil M, Zou Y, Yuan Z, Lu B, Jimeno J, Cuervo AM, Perez-Soler R.

Clin Cancer Res. 2013 Sep 1;19(17):4900. doi: 10.1158/1078-0432.CCR-13-1910. No abstract available.

10.

Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.

Martínez S, Pérez L, Galmarini CM, Aracil M, Tercero JC, Gago F, Albella B, Bueren JA.

Br J Pharmacol. 2013 Oct;170(4):871-82. doi: 10.1111/bph.12331.

11.

Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound.

Serova M, de Gramont A, Bieche I, Riveiro ME, Galmarini CM, Aracil M, Jimeno J, Faivre S, Raymond E.

Mar Drugs. 2013 Mar 20;11(3):944-59. doi: 10.3390/md11030944.

12.

Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.

García MJ, Saucedo-Cuevas LP, Muñoz-Repeto I, Fernández V, Robles MJ, Domingo S, Palacios J, Aracil M, Nieto A, Tercero JC, Benítez J.

Mol Cancer Ther. 2013 Apr;12(4):530-41. doi: 10.1158/1535-7163.MCT-12-0768. Epub 2013 Jan 30.

13.

Expression of XPG protein in human normal and tumor tissues.

Aracil M, Dauffenbach LM, Diez MM, Richeh R, Moneo V, Leal JF, Fernández LF, Kerfoot CA, Galmarini CM.

Int J Clin Exp Pathol. 2013;6(2):199-211. Epub 2013 Jan 15.

14.

Epithelial-mesenchymal transition markers and HER3 expression are predictors of elisidepsin treatment response in breast and pancreatic cancer cell lines.

Teixidó C, Marés R, Aracil M, Ramón y Cajal S, Hernández-Losa J.

PLoS One. 2013;8(1):e53645. doi: 10.1371/journal.pone.0053645. Epub 2013 Jan 8.

15.

ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.

Teixidó C, Arguelaguet E, Pons B, Aracil M, Jimeno J, Somoza R, Marés R, Ramón Y Cajal S, Hernández-Losa J.

Int J Oncol. 2012 Jul;41(1):317-24. doi: 10.3892/ijo.2012.1425. Epub 2012 Apr 3.

PMID:
22485250
16.

Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab.

Barboza NM, Medina DJ, Budak-Alpdogan T, Aracil M, Jimeno JM, Bertino JR, Banerjee D.

Cancer Biol Ther. 2012 Jan 15;13(2):114-22. doi: 10.4161/cbt.13.2.18876.

17.
18.

CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin.

Verrucci M, Pancrazzi A, Aracil M, Martelli F, Guglielmelli P, Zingariello M, Ghinassi B, D'Amore E, Jimeno J, Vannucchi AM, Migliaccio AR.

J Cell Physiol. 2010 Nov;225(2):490-9. doi: 10.1002/jcp.22228.

19.

Heparin and suramin alter plitidepsin uptake via inhibition of GPCR coupled signaling.

Longo-Sorbello GS, Gao H, Mishra PJ, Kamen B, Soto A, Jimeno J, Aracil M, Paz de Paz MF, Bertino JR, Banerjee D.

J Chemother. 2009 Nov;21(5):550-7.

PMID:
19933047
20.

Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.

Ling YH, Aracil M, Jimeno J, Perez-Soler R, Zou Y.

Eur J Cancer. 2009 Jul;45(10):1855-64. doi: 10.1016/j.ejca.2009.03.003. Epub 2009 Apr 5.

21.

Aplidin synergizes with cytosine arabinoside: functional relevance of mitochondria in Aplidin-induced cytotoxicity.

Humeniuk R, Menon LG, Mishra PJ, Saydam G, Longo-Sorbello GS, Elisseyeff Y, Lewis LD, Aracil M, Jimeno J, Bertino JR, Banerjee D.

Leukemia. 2007 Dec;21(12):2399-405. Epub 2007 Aug 23.

PMID:
17713546
22.

Levels of p27(kip1) determine Aplidin sensitivity.

Moneo V, Serelde BG, Leal JF, Blanco-Aparicio C, Diaz-Uriarte R, Aracil M, Tercero JC, Jimeno J, Carnero A.

Mol Cancer Ther. 2007 Apr;6(4):1310-6.

23.

SOCS up-regulation mobilizes autologous stem cells through CXCR4 blockade.

Pello OM, Moreno-Ortiz Mdel C, Rodríguez-Frade JM, Martínez-Muñoz L, Lucas D, Gómez L, Lucas P, Samper E, Aracil M, Martínez C, Bernad A, Mellado M.

Blood. 2006 Dec 1;108(12):3928-37. Epub 2006 Aug 15.

PMID:
16912231
24.
25.

The homeodomain protein Meis1 is essential for definitive hematopoiesis and vascular patterning in the mouse embryo.

Azcoitia V, Aracil M, Martínez-A C, Torres M.

Dev Biol. 2005 Apr 15;280(2):307-20.

26.

Wiskott-Aldrich syndrome protein is needed for vaccinia virus pathogenesis.

Guerra S, Aracil M, Conde R, Bernad A, Esteban M.

J Virol. 2005 Feb;79(4):2133-40.

27.

Telomere dynamics in Fancg-deficient mouse and human cells.

Franco S, van de Vrugt HJ, Fernández P, Aracil M, Arwert F, Blasco MA.

Blood. 2004 Dec 15;104(13):3927-35. Epub 2004 Aug 19.

PMID:
15319283
28.

Interleukin-6 deficiency affects bone marrow stromal precursors, resulting in defective hematopoietic support.

Rodríguez Mdel C, Bernad A, Aracil M.

Blood. 2004 May 1;103(9):3349-54. Epub 2003 Dec 30.

PMID:
14701687
29.

Selective inactivation of p27(Kip1) in hematopoietic progenitor cells increases neointimal macrophage proliferation and accelerates atherosclerosis.

Díez-Juan A, Pérez P, Aracil M, Sancho D, Bernad A, Sánchez-Madrid F, Andrés V.

Blood. 2004 Jan 1;103(1):158-61. Epub 2003 Sep 22.

30.

Long-term repopulating ability of telomerase-deficient murine hematopoietic stem cells.

Samper E, Fernández P, Eguía R, Martín-Rivera L, Bernad A, Blasco MA, Aracil M.

Blood. 2002 Apr 15;99(8):2767-75.

PMID:
11929765
31.

Expression and purification of human stromelysin 1 and 3 from baculovirus-infected insect cells.

del Mar Barbacid M, Fernández-Resa P, Buesa JM, Márquez G, Aracil M, Quesadaand AR, Mira E.

Protein Expr Purif. 1998 Jul;13(2):243-50.

PMID:
9675069
32.

Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3.

Mañes S, Mira E, Barbacid MM, Ciprés A, Fernández-Resa P, Buesa JM, Mérida I, Aracil M, Márquez G, Martínez-A C.

J Biol Chem. 1997 Oct 10;272(41):25706-12.

33.

SA-1, a nuclear protein encoded by one member of a novel gene family: molecular cloning and detection in hemopoietic organs.

Carramolino L, Lee BC, Zaballos A, Peled A, Barthelemy I, Shav-Tal Y, Prieto I, Carmi P, Gothelf Y, González de Buitrago G, Aracil M, Márquez G, Barbero JL, Zipori D.

Gene. 1997 Aug 22;195(2):151-9. Erratum in: Gene 1998 Jan 12;206(2):283.

PMID:
9305759
34.

Evaluation of fluorometric and zymographic methods as activity assays for stromelysins and gelatinases.

Quesada AR, Barbacid MM, Mira E, Fernández-Resa P, Márquez G, Aracil M.

Clin Exp Metastasis. 1997 Jan;15(1):26-32. Erratum in: Clin Exp Metastasis 1997 May;15(3):339-40.

PMID:
9009103
35.

Expression and purification of human matrilysin produced in baculovirus-infected insect cells.

López de Turiso JA, Fernández P, Barbacid MM, Mira E, Quesada AR, Márquez G, Aracil M.

J Biotechnol. 1996 May 15;46(3):235-41.

PMID:
8672291
36.
37.

Quantitative assay for cell invasion using the fluorogenic substrate 2',7'-Bis(2-carboxyethyl)-5 (and -6)-carboxyfluorescein acetoxymethylester.

Garrido T, Riese HH, Quesada AR, Barbacid MM, Aracil M.

Anal Biochem. 1996 Mar 15;235(2):234-6. No abstract available.

PMID:
8833333
38.

Chemosensitization and drug accumulation assays as complementary methods for the screening of multidrug resistance reversal agents.

Quesada AR, Barbacid MM, Mira E, Aracil M, Márquez G.

Cancer Lett. 1996 Jan 19;99(1):109-14.

PMID:
8564921
40.

Cell cycle arrest of human hematopoietic progenitors induced by medroxyprogesterone acetate.

Quesada AR, Jimeno JM, Márquez G, Aracil M.

Exp Hematol. 1993 Oct;21(11):1413-8.

PMID:
8405222
41.

Effect of ethanol on arachidonic acid metabolism in macrophages.

Schüller A, Aracil M, Diez E, Moscat J, Serrano Ríos M, Municio AM.

Riv Eur Sci Med Farmacol. 1991 May-Aug;13(3-4):105-13.

PMID:
1821045
42.

Hepatitis B surface antigen. Role of lipids in maintaining the structural and antigenic properties of protein components.

Gavilanes F, Gomez-Gutierrez J, Aracil M, Gonzalez-Ros JM, Ferragut JA, Guerrero E, Peterson DL.

Biochem J. 1990 Feb 1;265(3):857-64.

43.

Effect of ethanol on the arachidonic acid metabolism in mouse peritoneal macrophages.

Moscat J, Aracil M, Diez E, Garcia-Barreno P, Municio AM.

Prostaglandins. 1987 Dec;34(6):853-66.

PMID:
2835790
44.

Ethanol induces release of arachidonic acid but not synthesis of eicosanoids in mouse peritoneal macrophages.

Diez E, Balsinde J, Aracil M, Schüller A.

Biochim Biophys Acta. 1987 Sep 4;921(1):82-9.

PMID:
3113490
45.

Intracellular Ca2+ requirements for zymosan-stimulated phosphoinositide hydrolysis in mouse peritoneal macrophages.

Moscat J, Aracil M, Diez E, Balsinde J, Garcia Barreno P, Municio AM.

Biochem Biophys Res Commun. 1986 Jan 14;134(1):367-71.

PMID:
3004439

Supplemental Content

Loading ...
Support Center